Project Inform has published a new informative treatment guide for patients who have been recently been diagnosed with Hepatitis C. As the options for treating hepatitis C (HCV) are increasing, so is the confusion. This is a good problem to have: with more treatment options come more opportunities for people with various HCV genotypes (GT), treatment history and varying levels of cirrhosis to get cured. For more information visit: http://www.projectinform.org/hepc/i-have-hepatitis-c-what-are-my-treatment-options/
Pangaea will be reporting back from the annual Conference on Retroviruses and Opportunistic Infections (CROI), which brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases. CROI is a global model of collaborative science and the premier international venue for bridging basic and clinical investigation into clinical practice in the field of HIV and related viruses. CROI 2015 will be held from February 23 to February 26, 2015, in Seattle, Washington, at the Washington State Convention Center. For more information visit the CROI website www.croiconference.org.
This World AIDS Day is a promising one with several new HIV prevention interventions for young women on the horizon.
It is in Zimbabwe's best interest to prepare for these emerging strategies now. Just last year, HIV prevalence among pregnant women aged 15-24 in Zimbabwe was a startling 10.4 percent. This number is indicative of a larger trend in southern Africa where adolescent women are up to eight times more likely to become infected with HIV than young men.
Young women's high rates of HIV are due in part to biological, social and economic factors making them more susceptible. Because efforts to promote abstinence, monogamy and the use of male condoms have not been enough to stop HIV among girls and young women, researchers have been working to develop women-initiated biomedical prevention interventions. Years of scientific exploration here in Zimbabwe and around the world are finally starting to pay off. PrEP (pre-exposure prophylaxis), microbicide gels and rings are three methods that could potentially turn around the endemic rates of HIV in young women.
In the February 12, 2013, version of the Health and Human Services (HHS) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, the Panel recommendations on initial combination regimens for the antiretroviral therapy (ART)-naive, HIV-infected patient include raltegravir (RAL) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as the preferred integrase strand transfer inhibitor (INSTI)-based regimen, and elvitegravir (EVG)/cobicistat (cobi)/TDF/FTC as an alternative regimen for patients with estimated creatinine clearance (CrCl) ≥70 mL/min. Since the release of the Guidelines, a new INSTI, dolutegravir (DTG), was approved for use in ART-naive and ART-experienced patients. Additionally, long-term follow-up data (up to 144 weeks) from randomized clinical trials have demonstrated the durable safety and efficacy of EVG/cobi/TDF/FTC.
On the basis of these new findings, the Panel now recommends the following 4 INSTI-based regimens as preferred regimens for ART-naive patients (arranged in order of drug approval):
On 30th October 2013, Medecin Sans Frontieres launched a variety of new reports and advocacy tools at the Union Conference, including the DR-TB Drugs Under the Microscope, 3rd Edition report, and the "Test Me, Treat Me" TB Manifesto. You can find the press release by clicking here
The DR-TB Drugs Under the Microscope report aims to provide information on the prices, sources, access environment and R&D landscape for DR-TB medicines. It includes an analysis of the progress being made globally for the development of life-saving medicines for TB patients as well as the many remaining challenges. The report is available for download on our website, here.